SOPHIE Zenonos couldn’t climb the stairs without gasping for air, something she knew wasn’t normal. It took months for ...

Researchers at The University of Texas MD Anderson Cancer Center have characterized the complex microenvironment in ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

Eli Lilly (LLY) stock is in focus as its Jaypirca cancer drug succeeds in a Phase 3 trial for newly diagnosed patients with ...

Nick Patterson will make his debut in the Ballet's production of "The Nutcracker" a year after being diagnosed with cancer.

Marianne D'Amico-Ferrari has spent 29 years teaching in Trumbull. Families know her as steady and kind. Students describe her ...

A lifestyle intervention is feasible for patients with lymphoma undergoing chemotherapy, according to a study presented at ...

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel. Results presented at the 2025 ASH Annual Meeting & ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

In a new preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in blood ...